rs141412861
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_152296.5(ATP1A3):c.2886C>T(p.Pro962Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000434 in 1,613,936 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.000053 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000042 ( 0 hom. )
Consequence
ATP1A3
NM_152296.5 synonymous
NM_152296.5 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -4.76
Genes affected
ATP1A3 (HGNC:801): (ATPase Na+/K+ transporting subunit alpha 3) The protein encoded by this gene belongs to the family of P-type cation transport ATPases, and to the subfamily of Na+/K+ -ATPases. Na+/K+ -ATPase is an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane. These gradients are essential for osmoregulation, for sodium-coupled transport of a variety of organic and inorganic molecules, and for electrical excitability of nerve and muscle. This enzyme is composed of two subunits, a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). The catalytic subunit of Na+/K+ -ATPase is encoded by multiple genes. This gene encodes an alpha 3 subunit. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jan 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.75).
BP6
Variant 19-41967697-G-A is Benign according to our data. Variant chr19-41967697-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 468603.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-4.76 with no splicing effect.
BS1
Variant frequency is greater than expected in population afr. gnomad4_exome allele frequency = 0.0000424 (62/1461862) while in subpopulation AFR AF= 0.0000597 (2/33480). AF 95% confidence interval is 0.000038. There are 0 homozygotes in gnomad4_exome. There are 30 alleles in male gnomad4_exome subpopulation. Median coverage is 32. This position pass quality control queck.
BS2
High AC in GnomAd4 at 8 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ATP1A3 | NM_152296.5 | c.2886C>T | p.Pro962Pro | synonymous_variant | Exon 21 of 23 | ENST00000648268.1 | NP_689509.1 | |
ATP1A3 | NM_001256214.2 | c.2925C>T | p.Pro975Pro | synonymous_variant | Exon 21 of 23 | NP_001243143.1 | ||
ATP1A3 | NM_001256213.2 | c.2919C>T | p.Pro973Pro | synonymous_variant | Exon 21 of 23 | NP_001243142.1 | ||
ATP1A3 | XM_047438862.1 | c.2796C>T | p.Pro932Pro | synonymous_variant | Exon 21 of 23 | XP_047294818.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ATP1A3 | ENST00000648268.1 | c.2886C>T | p.Pro962Pro | synonymous_variant | Exon 21 of 23 | NM_152296.5 | ENSP00000498113.1 | |||
ENSG00000285505 | ENST00000644613.1 | n.2886C>T | non_coding_transcript_exon_variant | Exon 21 of 25 | ENSP00000494711.1 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152074Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
8
AN:
152074
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000558 AC: 14AN: 250970Hom.: 0 AF XY: 0.0000589 AC XY: 8AN XY: 135710
GnomAD3 exomes
AF:
AC:
14
AN:
250970
Hom.:
AF XY:
AC XY:
8
AN XY:
135710
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000424 AC: 62AN: 1461862Hom.: 0 Cov.: 32 AF XY: 0.0000413 AC XY: 30AN XY: 727230
GnomAD4 exome
AF:
AC:
62
AN:
1461862
Hom.:
Cov.:
32
AF XY:
AC XY:
30
AN XY:
727230
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000526 AC: 8AN: 152074Hom.: 0 Cov.: 31 AF XY: 0.0000539 AC XY: 4AN XY: 74272
GnomAD4 genome
AF:
AC:
8
AN:
152074
Hom.:
Cov.:
31
AF XY:
AC XY:
4
AN XY:
74272
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Dystonia 12 Benign:2
Dec 24, 2024
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Dec 05, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
not specified Benign:1
Mar 16, 2021
Athena Diagnostics
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Alternating hemiplegia of childhood 2 Benign:1
Dec 05, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
not provided Benign:1
May 01, 2023
CeGaT Center for Human Genetics Tuebingen
Significance: Likely benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
ATP1A3: BP4, BP7 -
Developmental and epileptic encephalopathy 99 Benign:1
Dec 05, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Cerebellar ataxia-areflexia-pes cavus-optic atrophy-sensorineural hearing loss syndrome Benign:1
Dec 05, 2021
Genome-Nilou Lab
Significance: Benign
Review Status: criteria provided, single submitter
Collection Method: clinical testing
- -
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at